Previous 10 | Next 10 |
ANJESO ® Revenue Up 40% in Q3 2021 over Q2 2021 and Up Over 300% in Q3 2021 over Q3 2020 Solid Growth in End User Demand Units, September 2021 Strongest Month Launch-to-Date, Indicating Growing Adoption of ANJESO Neuromuscular Blocking Agent BX1000 Compl...
ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...
Baudax Bio (NASDAQ:BXRX) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.16 and the consensus Revenue Estimate is $0.6M (+757.1% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward...
MALVERN, Pa., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that it will report third quarter 2021 financial results on Thursday, November 4, 2...
Featuring Baudax Bio (BXRX), BioElectronics Corporation (BIEL), electroCore (ECOR), Heron Therapeutics (HRTX), MedX Health (MDXHF), Virpax Pharmaceuticals (VRPX) - Presented by Channelchek and Noble Capital Markets Read More >>
Baudax Bio President and CEO Gerri Henwood - New Developments in Pain Management - a NobleCon Online Investor Event. Each presentation features a formal corporate overview, followed by a Q & A session moderated by Noble Capital Markets Senior Healthcare Services & Medical Devices Analy...
MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that management will give a corporate presentation followed by a question and answe...
“No pain, no gain” is a motivational gym saying used for years. Investors have found the saying also applies to portfolio gains. The pain management industry is rapidly growing and now provides an even broader spectrum of publicly traded opportunities. Why? Reduced opioid use has...
NobleCon Online Investor Event - New Developments in Pain Management - October 7, 2021 Exclusively on Channelchek - Featuring Baudax Bio (BXRX), BioElectronics Corporation (BIEL), Heron Therapeutics (HRTX), MedX Health (MDXHF), NanoVibronix (NAOV), Virpax Pharmaceuticals (VRPX) Read More >...
The following slide deck was published by Baudax Bio, Inc. in conjunction with this event. For further details see: Baudax Bio (BXRX ) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023